KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Cash & Equivalents (2016 - 2026)

Palvella Therapeutics has reported Cash & Equivalents over the past 10 years, most recently at $38.6 million for Q4 2022.

  • Quarterly Cash & Equivalents fell 67.19% to $38.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $38.6 million through Dec 2022, down 67.19% year-over-year, with the annual reading at $38.6 million for FY2022, 67.19% down from the prior year.
  • Cash & Equivalents was $38.6 million for Q4 2022 at Palvella Therapeutics, down from $69.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $125.1 million in Q3 2021 and troughed at $38.6 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $66.9 million (2020), against an average of $70.7 million.
  • Year-over-year, Cash & Equivalents skyrocketed 107.21% in 2021 and then tumbled 67.19% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $71.9 million in 2018, then fell by 13.46% to $62.3 million in 2019, then increased by 13.13% to $70.4 million in 2020, then skyrocketed by 67.19% to $117.8 million in 2021, then plummeted by 67.19% to $38.6 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Cash & Equivalents are $38.6 million (Q4 2022), $69.8 million (Q3 2022), and $54.3 million (Q2 2022).